Related references
Note: Only part of the references are listed.Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus
D. C. Salazar-Camarena et al.
LUPUS (2016)
Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial
R. F. van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2015)
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study
R. A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
David Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Systemic lupus erythematosus
Larissa Lisnevskaia et al.
LANCET (2014)
The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved
Ole Petter Rekvig et al.
SEMINARS IN IMMUNOPATHOLOGY (2014)
Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus
A. Schmeding et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2013)
Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort
Eoghan M. McCarthy et al.
RHEUMATOLOGY (2013)
The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey
Caroline Gordon et al.
RHEUMATOLOGY (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Unmet medical needs in systemic lupus erythematosus
Aisha Lateef et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Results of a Phase II, Randomized, Placebo-Controlled Trial
R. F. van Vollenhoven et al.
ARTHRITIS AND RHEUMATISM (2011)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Raised serum level of APRIL in patients with systemic lupus erythematosus: Correlations with disease activity indices
M. Hegazy et al.
CLINICAL IMMUNOLOGY (2010)
Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF
Miyo Ota et al.
JOURNAL OF IMMUNOLOGY (2010)
Prednisone, Lupus Activity, and Permanent Organ Damage
Mae Thamer et al.
JOURNAL OF RHEUMATOLOGY (2009)
An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus
C. Pena-Rossi et al.
LUPUS (2009)
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
Elodie Belnoue et al.
BLOOD (2008)
Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL
Micah J. Benson et al.
JOURNAL OF IMMUNOLOGY (2008)
EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics
G. Bertsias et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus
Maria Dall'Era et al.
ARTHRITIS AND RHEUMATISM (2007)
Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus
Shaoqing Ju et al.
CLINICAL BIOCHEMISTRY (2006)
Mortality in systemic lupus erythematosus
S. Bernatsky et al.
ARTHRITIS AND RHEUMATISM (2006)
Raised serum APRIL levels in patients with systemic lupus erythematosus
T Koyama et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
DA Isenberg et al.
RHEUMATOLOGY (2005)
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus
W Stohl et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients
R Cervera et al.
MEDICINE (2003)
Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus
J Zhang et al.
JOURNAL OF IMMUNOLOGY (2001)
APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity
G Yu et al.
NATURE IMMUNOLOGY (2000)
Share Paper
